Liso-cel Leukemia: Superior Outcomes vs. Standard Care
- CHICAGO — Lisocabtagene maraleucel (liso-cel) significantly improved survival outcomes and response rates in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), according to research presented at the...
- The study compared liso-cel to standard of care treatments in patients with CLL who had relapsed or were refractory to previous therapies.
- The FDA approved lisocabtagene maraleucel (Breyanzi) for relapsed or refractory CLL or small lymphocytic lymphoma (SLL) based on the TRANSCEND CLL 004 trial results.
Liso-cel demonstrated superior outcomes compared to standard care for relapsed or refractory chronic lymphocytic leukemia (CLL). The study found that patients treated with liso-cel achieved considerably improved survival rates and response rates. researchers compared liso-cel to standard treatments, including chemotherapy and immunotherapy. Key findings reveal a higher objective response rate (ORR),longer progression-free survival (PFS),and extended overall survival (OS) in the liso-cel group. the FDA approved liso-cel (Breyanzi) based on these compelling results from the TRANSCEND CLL 004 trial. This marks a ample advancement in CLL treatment, offering hope for patients facing limited options. News Directory 3 provides the latest oncology updates. what’s next in leukemia treatment innovations?
Lisocabtagene Maraleucel (liso-cel) Improves Survival in Relapsed CLL
CHICAGO — Lisocabtagene maraleucel (liso-cel) significantly improved survival outcomes and response rates in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), according to research presented at the ASCO Annual Meeting.
The study compared liso-cel to standard of care treatments in patients with CLL who had relapsed or were refractory to previous therapies. William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, and colleagues, noted that those who fail Bruton tyrosine kinase inhibitors and venetoclax face limited options and poor prognoses.
The FDA approved lisocabtagene maraleucel (Breyanzi) for relapsed or refractory CLL or small lymphocytic lymphoma (SLL) based on the TRANSCEND CLL 004 trial results.
Researchers compared 66 patients from the TRANSCEND CLL 004 trial who received lisocabtagene maraleucel with an external control group of 212 patients from the Flatiron, COTA, and concertai clinical trials who received standard of care.
Standard treatments included chemotherapy, immunotherapy (excluding CAR-T therapy), Bruton tyrosine kinase inhibitors, venetoclax, PI3K inhibitors, and combinations of these.
The primary goals were to measure objective response rate (ORR), progression-free survival (PFS), and overall survival (OS).
The median follow-up was 35.4 months for the liso-cel group and 17.2 months for the standard of care group.
The objective response rate with liso-cel was 52.5%, compared to 19.2% with standard care.
Median progression-free survival in the liso-cel group was 12 months, versus 4.4 months in the standard of care group. The probabilities of PFS at 24 and 36 months were 46.3% and 30.3% with liso-cel, compared to 11.5% and 5.1% with standard care.
The median overall survival was 33.6 months with liso-cel and 14.8 months with standard care. The probabilities of OS at 24 months were 73.4% with liso-cel, and 42.6% at 36 months, compared to 35.1% and 29.7% with standard care.